{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-006051","form_type":"8-K","ticker":"REVB","cik":"0001810560","company_name":"REVELATION BIOSCIENCES, INC.","filed_at":"2024-01-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.623857+00:00","generated_at":"2026-06-06T20:45:36.774347+00:00","sec_items":["5.07","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Revelation Biosciences shareholders approve reverse stock split (1:2 to 1:50)","bullets":["Reverse stock split authorized with ratio range 1-for-2 to 1-for-50; board to set exact ratio within one year.","Proposal 1 votes: 1,410,313 For, 831,173 Against, 2,562 Abstain.","Proposal 2 to adjourn if needed also approved: 1,676,035 For, 551,758 Against, 16,255 Abstain.","Special Meeting held Jan 17, 2024; quorum of 2,244,048 shares of 6,297,303 outstanding.","Board has sole discretion to implement split at any time within one year without further shareholder vote."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-006051","json":"https://secwatch.observer/filing/0000950170-24-006051.json","markdown":"https://secwatch.observer/filing/0000950170-24-006051.md","text":"https://secwatch.observer/filing/0000950170-24-006051.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1810560/000095017024006051/0000950170-24-006051-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1810560/000095017024006051/revb-20240117.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T20:45:36.774347+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"50b1e9f2cb27a9d6d249e7b653c8c3bc6ccacbb7","claim":"REVELATION BIOSCIENCES, INC. shareholders approved Approve adjournment of the Special Meeting to the extent there are insufficient proxies to approve the Reverse Stock Split at the 2024-01-17 meeting.","evidence_excerpt":"Stockholders approved of the adjournment of the Special Meeting to the extent there are insufficient proxies at the Special Meeting to approve the Reverse Stock Split, based on the votes listed below: For Against Abstain 1,676,035 551,758 16,255","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1810560/000095017024006051/0000950170-24-006051-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"reverse split"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2024-01-17"}],"fact_type":"shareholder_vote"},{"claim_id":"f8d5fa289fdfcb1b58038d3ae306947ab3c112bd","claim":"REVELATION BIOSCIENCES, INC. shareholders approved Approve grant of discretionary authority to board of directors to effect a reverse stock split at a ratio within a range of one-for-2 to one-for-50 at the 2024-01-17 meeting.","evidence_excerpt":"Stockholders approved the board of directors to effect a Reverse Stock Split of the outstanding shares of our common stock within one (1) year of January 17, 2024, at a specific ratio within a range of one-for-2 to a maximum of a one-for-50 split, with the specific ratio to be fixed within this range by the board of directors in its sole discretion without further stockholder approval, based on the votes listed below: For Against Abstain 1,410,313 831,173 2,562","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1810560/000095017024006051/0000950170-24-006051-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"reverse split"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2024-01-17"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}